Business Wire

MA-ECHOSENS

28.7.2022 14:59:08 CEST | Business Wire | Press release

Share
Echosens Partners with World Hepatitis Alliance on World Hepatitis Day, July 28, Urges Importance of Testing and Treatment

Echosens , a high-technology company offering liver diagnostic solutions, establishes its support of World Hepatitis Day (WHD), July 28 by partnering with the World Hepatitis Alliance as a bronze sponsor . The commemoration calls for greater awareness of the 357 million people who live with viral hepatitis but are unaware of it. The campaign’s theme “I can’t wait” highlights the need to accelerate the fight against viral hepatitis and the importance of testing and treatment for the real people who need it.

“Echosens recognizes that every 30 seconds , someone in the world dies from a hepatitis-related illness, and we join hands with organizations throughout the world to advance increased vigilance around liver health,” says Dominque Legros, Echosens Group CEO. “It is gratifying to see that this year's theme for World Hepatitis Day aligns with our mission for early detection that can result in more effective intervention, treatment and better outcomes.”

Viral hepatitis is an inflammation of the liver and a major public health concern worldwide that – until recently - has garnered little notice. Even though the disease kills about 1.5 million people globally every year, the majority of people who contract the disease are unaware until they develop acute symptoms.

"Hepatitis is the leading cause of liver cancer,” says Jon Gingrich, CEO, Echosens, North America. “Assessing the degree of fibrosis is a crucial step in the clinical management of individuals with viral infection and key to detecting asymptomatic patients, helping to prioritize care and to selecting treatment regimens. Liver disease is reversible with early, non-invasive testing, exemplified by FibroScan, to identify and monitor liver health.”

All types of viral hepatitis can be controlled or prevented. In 2016, the World Health Organization’s World Health Assembly called for global elimination of viral hepatitis by 2030 and individual countries are now in different stages of developing their own viral hepatitis elimination plans.

"This international campaign will bring the World Hepatitis Alliance and our global network of over 300 members across 100 countries together to demand action from decision makers to prioritize the elimination of viral hepatitis – one of the most deadly and neglected diseases,” says Danjuma Adda, president, World Hepatitis Alliance. “This event will also highlight the social injustice and inequity caused by the current lack of action on eliminating viral hepatitis and focus on the positive action needed to eradicate this disease as a public health threat by 2030. Our sponsors reaffirm their commitment to making this goal a reality.”

About Echosens
Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan® , the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 3,500 peer reviewed publications and 160 international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/

Link:

ClickThru

Social Media:

https://www.facebook.com/fibroscan.echosens

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh

Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting26.3.2026 21:30:00 CET | Press release

Spring is in full swing at the “World’s Most Famous Building.” The Empire State Building (ESB) today announced a vibrant lineup of spring events in NYC, which include special experiences, treat pop-ups, and an iconic tower lighting that captures the joy and color of the beautiful season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326216271/en/ Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting “The Empire State Building Observation Deck has transformed into a celebration of the season and one of the best things to do in NYC this spring,” said Dan Rogoski, observatory general manager. “Whether it’s views beside our butterfly installation, sweet pop-ups, or a chance to spot the Easter Bunny, there is something special for every visitor.” Flutter of Color: The Empire State Building installed a brand-new photo opportunity on the 86th Floor Observati

Venture Global and Edison Announce Calcasieu Pass Arbitration Settlement26.3.2026 21:15:00 CET | Press release

Today, Venture Global and Edison jointly announced the signature of a commercial agreement for the settlement of the pending arbitration between the two companies concerning the Calcasieu Pass project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326559130/en/ Completion of the settlement is expected by the end of Q2 2026, at which point the arbitration will be terminated. The agreement fully resolves the arbitration in its entirety. As part of the settlement, Edison and Venture Global have also agreed to the delivery to Europe of additional cargoes beyond those envisaged under the long-term contract, to support gas supplies primarily to the Italian market. The first delivery is scheduled for May 2026, in Italy, at the Adriatic LNG Terminal. The agreement represents a significant step in strengthening commercial cooperation between the parties and it establishes a foundation for further future deliveries in the context

Reply Recognized as a Microsoft Frontier Partner for Enterprise AI Delivery26.3.2026 19:06:00 CET | Press release

Reply [EXM, STAR: REY] announces it has been recognized as a Microsoft Frontier Partner within the Microsoft AI Cloud Partner Program, earning the Frontier Partner Badge for demonstrating advanced capabilities in delivering AI-first solutions across Cloud & AI Platforms, AI Business Solutions, and Security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326965586/en/ The recognition reflects Reply’s capabilities across the Microsoft ecosystem, built through the work of its specialized companies – including Aim Reply, Business Elements Reply, Cluster Reply, Root16 Reply, Solidsoft Reply, Valorem Reply, WM Reply and Zest Reply – supporting enterprise organizations in designing, implementing, and operating AI solutions on Microsoft platforms across real-world business scenarios. The Frontier Partner badge recognizes partners that demonstrate advanced AI driven capabilities and meet rigorous badge requirements at the time of

SLB Announces Dates for First-Quarter 2026 Results Conference Call26.3.2026 18:00:00 CET | Press release

SLB (NYSE:SLB) will hold a conference call on April 24, 2026, to discuss the results for the first quarter ending March 31, 2026. The conference call is scheduled to begin at 11:00 a.m. US Eastern time and a press release regarding the results will be issued at 7:00 a.m. US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (833) 470-1428 within North America or +1 (404) 975-4839 outside of North America approximately 10 minutes prior to the start of the call and the access code is 742955. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/972985185 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until May 1, 2026, and can be accessed by dialing +1 (866) 813-9403 within North America or +1 (929)

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye